Northern Ireland’s growing life sciences sector is set to benefit from closer collaboration with the UK regulator, as the Medicines and Healthcare products Regulatory Agency (MHRA) establishes a new hub in Belfast.
The move will see the MHRA hosted at Invest Northern Ireland’s offices, strengthening links between regulators, industry, academia and healthcare providers across the region.
The new hub builds on the MHRA’s existing partnerships across the UK, ensuring its work is more closely connected to all parts of the country.
By embedding a presence in Northern Ireland, the regulator aims to support a more integrated approach to innovation and ensure that regional strengths in research and development are fully utilised.
Northern Ireland already has a significant and expanding life sciences sector, with around 250 companies employing 18,000 people and contributing £1.1 billion annually to the local economy.
A key feature of the initiative will be improved access to MHRA expertise for local organisations.
Through regular, in‑person “surgery sessions” at the Belfast hub, businesses, researchers and clinicians will be able to meet directly with MHRA experts to discuss:
- Regulatory pathways for innovation
- Clinical investigations and trials
- Product development and approval processes
This hands‑on support is designed to help organisations navigate complex regulatory requirements more effectively and bring new therapies and technologies to market more quickly.
By strengthening connections between regulators and the life sciences sector, the hub is expected to play an important role in accelerating the development of new medicines and medical technologies.
Improved access to advice and guidance throughout the development process can help reduce delays, support clinical research and ensure that potentially life‑saving treatments reach patients sooner.
The initiative reflects a broader effort to create a more responsive regulatory environment that supports innovation while maintaining high standards of safety and quality.
The announcement follows a series of stakeholder engagement activities already underway in Northern Ireland.
The MHRA recently hosted events at the HIRANI Health Tech Spring Conference in Belfast, showcasing how it supports innovation and clinical investigations.
Further events are planned, focusing on areas of interest to the local sector and strengthening relationships with organisations across healthcare, research and industry.
The MHRA’s presence in Northern Ireland also supports the expansion of its Yellow Card scheme, which allows patients and healthcare professionals to report suspected side effects from medicines and devices.
Greater uptake of the scheme in Northern Ireland is expected to improve data collection and safety monitoring, helping to identify potential issues earlier and enhance patient protection.
Northern Ireland has established itself as a key player in the global life sciences landscape, with strengths in:
- Precision medicine
- Pharmaceuticals and biotechnology
- Diagnostics and medical technology
The region is also recognised for its clinical trials capability, supported by an integrated health and social care system, advanced research facilities and strong digital infrastructure.
The new MHRA hub is expected to further enhance this reputation, attracting investment and supporting continued growth.
The hub builds on commitments made following an MHRA Board meeting in Belfast in November 2025, co‑chaired by the agency’s leadership and Northern Ireland’s Chief Pharmaceutical Officer.
Professor Anthony Harnden, Chair of the MHRA, said:
“One of my priorities since becoming chair has been to ensure the MHRA is a regulator for all nations with an increased presence and engagement with our partners and stakeholders across the UK.
“MHRA’s Board seminar in Belfast last year signalled our commitment to supporting the life sciences sector in Northern Ireland to meet the 21st century challenges presented by new technologies such as personalised medicines and AI and embrace innovation whilst always putting the best interests of patients and the public first.”
By establishing a permanent presence, the MHRA is reinforcing its commitment to regional collaboration and long‑term engagement with Northern Ireland’s life sciences community.
By connecting local expertise with national regulatory support, the hub aims to:
- Strengthen the life sciences ecosystem
- Support economic growth
- Improve healthcare outcomes
With the new Belfast hub now being established, stakeholders across the sector are expected to benefit from closer relationships, improved access to expertise and greater opportunities for collaboration.
The initiative marks an important step in supporting the continued growth of Northern Ireland’s life sciences sector while ensuring patients benefit from faster access to innovative treatments.
Image credit: iStock
